Oslo, Norway, October 12, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today presents at the annual mRNA Cancer
Vaccines Summit in Boston, Massachusetts. 

The presentation is held by Mikkel W. Pedersen, Chief Scientific Officer at
Nykode. The presentation slides are enclosed and available in the Scientific
Papers and Presentations section of the Company's website at:
https://nykode.com/innovation-and-research/scientific-papers-and-presentations/.

Details for the Nykode Therapeutics' presentation are as follows:
Title: Opportunities to improve mRNA Cancer Vaccines
Time & Date: 10.00 a.m. ET, October 12, 2023


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on treatment
of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to APC, which have been shown to induce broad,
strong and long-lasting antigen specific immune responses which correlates with
clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer